IP Library Granted Patent US 7,771,389
Granted Patent B2
US 7,771,389 · App. 11/073,892 · Granted Aug 10, 2010

Injector auto purge

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,771,389
App. No.
11/073,892
Granted
Aug 10, 2010
Kind
B2
Abstract

An auto purge for an intravenous contrast injector of the type having a motor which advances a plunger drive ram and configured for use with a pre-filled or user-filled syringe containing an approximate known amount of air including a processor which causes the motor to move and a memory storing a predetermined purge stop point representative of the approximate known amount of air in the syringe, the injector configured to automatically advance the plunger drive ram an amount substantially equal to the predetermined purge stop point representative of the approximate known amount of air contained in the syringe.

Claims (41)

1. A medical fluid injector comprising:

a syringe having:

a barrel that includes a discharge tip; and

a plunger disposed within and movable relative to the barrel;

a motorized plunger drive ram configured to move the plunger of the syringe within and relative to the barrel of the syringe both toward and away from the discharge tip of the syringe;

a processor which controls movement of the plunger drive ram, the processor configured with a purge sequence designed to force air and/or gas from the syringe via the discharge tip prior to fluidly connecting the syringe with a patient, the processor being further configured with an injection protocol designed to inject medical fluid into a patient when the syringe is fluidly connected with a patient; and

a tilt sensor, wherein an output from the tilt sensor allows for execution of the purge sequence only when the discharge tip of the syringe is pointed upward, wherein an output from the tilt sensor allows for execution of the injection protocol when the discharge tip of the syringe is pointed downward, and wherein the purge sequence includes:

the plunger drive ram moving the plunger within the barrel of the syringe and toward the discharge tip of the syringe an amount substantially equal to a predetermined stop point; and

a low flow rate that is enabled upon the plunger drive ram reaching the predetermined stop point, wherein the low flow rate is a flow rate at which medical fluid is expelled from the discharge tip of the syringe due to the plunger drive ram moving the plunger within the barrel of the syringe, and wherein the low flow rate is no more than about 1 ml/sec.

2. The injector of claim 1 , wherein the low flow rate is no more than about 0.5 ml/sec.

3. The injector of claim 1 , wherein the medical fluid comprises contrast media.

4. The injector of claim 1 , wherein the syringe is designed to allow medical fluid to enter the barrel thereof via the discharge tip.

5. The injector of claim 4 , wherein the low flow rate is no more than about 0.5 ml/sec.

6. The injector of claim 4 , wherein the syringe is designed to allow medical fluid from within the barrel thereof to be discharged from the syringe via the discharge tip.

7. The injector of claim 1 , wherein the syringe is designed to allow medical fluid from within the barrel thereof to be discharged from the syringe via the discharge tip.

8. The injector of claim 5 , wherein the low flow rate is no more than about 0.5 ml/sec.

9. The injector of claim 1 , wherein the predetermined stop point is based on at least one parameter of the syringe.

10. The injector of claim 9 , wherein the low flow rate is no more than about 0.5 ml/sec.

11. The injector of claim 1 , wherein the predetermined stop point is user adjusted.

12. The injector of claim 11 , wherein the low flow rate is no more than about 0.5 ml/sec.

13. The injector of claim 1 , wherein the predetermined stop point is calibrated.

14. The injector of claim 13 , wherein the low flow rate is no more than about 0.5 ml/sec.

15. The injector of claim 1 , wherein the predetermined stop point is based on historical information.

16. The injector of claim 15 , wherein the low flow rate is no more than about 0.5 ml/sec.

17. The injector of claim 1 , wherein the low flow rate is applicable to a manual movement control of the injector.

18. The injector of claim 17 , wherein the low flow rate is no more than about 0.5 ml/sec.

19. The injector of claim 1 , wherein the low flow rate is applicable to an automatic purge of medical fluid from the syringe until the automatic purge is stopped by operator input.

20. The injector of claim 19 , wherein the low flow rate is no more than about 0.5 ml/sec.

21. The injector of claim 1 , wherein the processor is configured to advance the plunger drive ram to provide an initial flow rate until reaching the predetermined stop point, wherein the initial flow rate is a flow rate at which medical fluid is expelled from the discharge tip of the syringe due to the plunger drive ram moving the plunger within the barrel of the syringe, and wherein the initial flow rate is greater than the low flow rate.

22. A medical fluid injector comprising:

a syringe comprising a barrel and a plunger, the barrel comprising a discharge tip, and the plunger being disposed within and movable relative to the barrel;

a motorized plunger drive ram configured to move the plunger of the syringe within and relative to the barrel of the syringe both toward and away from the discharge tip of the syringe;

a processor which controls movement of the plunger drive ram, the processor being configured with a purge sequence designed to force air and/or gas from the syringe via the discharge tip prior to fluidly connecting the syringe with a patient, the processor being further configured with an injection protocol designed to inject medical fluid into a patient when the syringe is fluidly connected with a patient; and

a tilt sensor, wherein an output from the tilt sensor allows for execution of the purge sequence only when the discharge tip of the syringe is pointed upward, wherein an output from the tilt sensor allows for execution of the injection protocol when the discharge tip of the syringe is pointed downward, and wherein the purge sequence comprises:

a first purge portion comprising a programmed advancement of the plunger drive ram at a first purge flow rate and in a direction that moves the plunger within the barrel of the syringe and toward the discharge tip of the syringe; and

a second purge portion comprising advancement of the plunger drive ram at a second purge flow rate and in a direction that moves the plunger within the barrel of the syringe and toward the discharge tip of the syringe, the second purge portion being available only after completion of the first purge sequence segment, and the second purge flow rate being less than the first purge flow rate.

23. The injector of claim 22 , wherein the second purge flow rate is no more than about 1 ml/sec.

24. The injector of claim 22 , wherein the first purge portion further comprises terminating advancement of the plunger drive ram, and wherein user input is required to initiate the second purge portion.

25. The injector of claim 24 , wherein the first purge portion is terminated upon reaching a predetermined stop point.

26. The injector of claim 22 , wherein the second purge portion comprises using a hand-operated movement control associated with the plunger drive ram.

27. The injector of claim 22 , wherein the second purge portion comprises a programmed advancement of the plunger drive ram.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 037172/0094 →